Kelkar, P., Masood, M
Conclusion This review synthesizes current evidence to summarize the therapeutic potential and underlying mechanisms of nanozymes in IMIDs, while highlighting key challenges and future directions to guide the development and clinical translation of nanozyme-based therapies
Researchers may compare GHK-Cu with materials such as BPC-157, TB-500, GLOW Blend, and KPV when the study design supports that comparison
ALP, GGT, and 5-NT have also been used as markers of bile duct injury and cholestasis
BPC-157 versus TB-500: 2026 comparison, opposing mechanisms, preclinical data, and the myth of the Wolverine stack BPC-157 and TB-500 are the two most discussed regenerative peptides in preclinical research
Genistein can downregulate miR-95 [190, 191]